Moderna and IBM Plan to Collaborate on COVID-19 Vaccine Supply Chain and Distribution Data Sharing

IBMModerna (Nasdaq: MRNA) and IBM (NYSE: IBM) announced their intentions to explore technologies, including artificial intelligence, blockchain and hybrid cloud, that could help support smarter COVID-19 vaccine management. Central to the effort will be a pilot of open, standardized, technology-enabled vaccine distribution approaches aimed to improve supply chain visibility and foster near real-time tracking of vaccine administration.

The aim is to identify ways technology can be used to help accelerate secure, information sharing between governments, healthcare providers, life science organizations and individuals. In so doing, Moderna and IBM seek to improve confidence in vaccine programs and increase rates of vaccination, thereby reducing community spread.

Initial work is planned to focus on exploring the utility of IBM capabilities in the U.S. including:

  • Vaccine management solutions that provide end-to-end traceability to address potential supply chain disruptions. The solutions enable governments and healthcare providers to quickly and securely share data regarding individual vaccine batches as they travel through the complex COVID-19 supply chain, from manufacturing facilities to administration sites.
  • Digital Health Pass, built on blockchain technology, is a solution designed to help individuals maintain control of their personal health information and share it in a way that is secured, verifiable and trusted. Organizations can use the solution to verify health credentials for employees, customers and travelers based on criteria specified by the organization, such as test results, vaccination records and temperature checks.

"Moderna is committed to working with a coalition of partners to increase education and awareness of the importance of vaccination to help defeat COVID-19," said Michael Mullette, VP, Managing Director North America Commercial Operations of Moderna. "We look forward to working with IBM to apply digital innovations to build connections between organizations, governments, and individuals to instill confidence in COVID-19 vaccines."

"If ever there was a time to rally around open technology and collaboration, it's now," said Jason Kelley, Managing Partner, Global Strategic Alliances Leader for IBM. "As governments, pharmacy chains, healthcare providers and life sciences companies continue to scale and connect their tools, and as new players enter the supply chain, open technology can help drive more transparency and bolster trust, while helping to ensure accessibility and equity in the process."

The work with Moderna aligns with IBM's efforts to help address the COVID-19 pandemic by providing access to its technology portfolio. At the outset of the pandemic, IBM joined the White House Office of Science and Technology Policy and other technology companies as part of the COVID-19 High Performance Computing Consortium, a partnership to give supercomputing resources to researchers to help speed the discovery and development of COVID-19 vaccines. IBM also offered its IBM Clinical Development (ICD) solution to eligible trial sponsor organizations as part of its medical community support efforts to help address the pandemic. The company received interest from numerous hospitals, sponsors, contract research organizations and academic institutions.

About IBM

Statements regarding IBM's future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the promising-but-still-unproven field of messenger RNA (mRNA), to an enterprise with its first medicine having treated millions of people, a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years.

Most Popular Now

Early Warning System for Intensive Care …

Life-threatening situations occur time and again in an intensive care unit. To make sure that doctors can intervene in time, a team at the German Heart Center Berlin (DHZB) has...

Virtual Reality could Help to Reduce Pai…

We all feel physical pain in different ways, but people with nerve injuries often have a dysfunctional pain suppression system, making them particularly prone to discomfort. Now researchers have uncovered that...

Philips Partners with Orbita to Develop …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Orbita Inc., an innovative provider of conversational artificial intelligence (AI) solutions for healthcare, announced a partnership agreement...

CliniSys Group Creates Single Brand for …

CliniSys Group has created a single brand for its businesses in the UK and Europe, with a refreshed logo and a new website. The move creates a unified identity for CliniSys...

East Lancashire Signs Deal for Early War…

Thousands of NHS professionals across five hospitals in East Lancashire are to benefit from early warning technology that will help them detect and swiftly respond to deteriorating patients in need...

FDA Grants Oxehealth Vital Signs De Novo…

Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the...

Telemedicine Improves Access to High-Qua…

The American Academy of Sleep Medicine recently published an update on the use of telemedicine for the diagnosis and treatment of sleep disorders to reflect lessons learned from the transition...

DMEA 2021: Digital Health. 100 % Virtual…

7 - 11 June 2021, Berlin, Germany. An entire week dominated by digital healthcare! With that in mind, early in June DMEA 2021 will be kicking off with a wide range...

Philips and NHS Implement the First Regi…

Royal Philips (NYSE: PHG, AEX: PHIA), announced it has supported the NHS' Cheshire and Merseyside consortium [1] to become the first regional hub supplying the United Kingdom's National COVID-19 Chest...

Child Brain Tumours can be Classified by…

Diffusion weighted imaging and machine learning can successfully classify the diagnosis and characteristics of common types of paediatric brain tumours a UK-based multi-centre study, including WMG at the University of...

AI could Crack the Language of Cancer an…

Powerful algorithms used by Netflix, Amazon and Facebook can 'predict' the biological language of cancer and neurodegenerative diseases like Alzheimer's, scientists have found.